# Internal Review — Claude Code (Round 1)

**Role:** Internal self-review (Reviewer 2 mode)
**Reviewer:** Claude Code (claude-opus-4-6)
**Paper:** Can Drug Checking Save Lives? Evidence from Staggered Fentanyl Test Strip Legalization
**Timestamp:** 2026-02-11T17:16:00

---

## 1. FORMAT CHECK

- **Length:** 35 pages including appendix and references. Main text is approximately 27 pages before references. Meets threshold.
- **References:** 27 entries covering key DiD methodology (Callaway & Sant'Anna, Sun & Abraham, Goodman-Bacon, Rambachan & Roth, Borusyak et al.), policy literature (McKnight 2024, Rees et al. 2019), and FTS-specific studies. Added Abadie et al. (2010), Cameron et al. (2008), Peltzman (1975) per reviewer suggestions.
- **Prose:** All major sections are in paragraph form. No bullet points in main text.
- **Section depth:** Each section has 3+ substantive paragraphs.
- **Figures:** 5 figures (rollout, trends, event study, estimator comparison, RI) with clear axes and labels.
- **Tables:** 9 tables with real data. No placeholders.

## 2. STATISTICAL METHODOLOGY

- **Standard errors:** Present for all coefficients. Bootstrap SEs (1,000 iterations) clustered at state level for CS-DiD.
- **Significance testing:** p-values reported; RI p-value from 1,000 permutations.
- **Confidence intervals:** 95% CIs for main CS estimates and HonestDiD bounds.
- **Sample sizes:** N=423 state-years, 47 clusters reported consistently.
- **DiD with staggered adoption:** Uses Callaway-Sant'Anna (never-treated comparison) as primary; Sun-Abraham as robustness. TWFE reported as benchmark with caveats.

No fatal methodological issues.

## 3. IDENTIFICATION STRATEGY

The identification is credible but fragile — which the paper honestly acknowledges. Strengths include: modern estimators, HonestDiD sensitivity, RI, leave-one-out analysis, and state-specific trends. The pre-treatment CS coefficient at e=-2 is concerning but addressed through HonestDiD and the divergence between CS and SA pre-trends. The small comparison group (8 states) is a genuine limitation that future work with expanded data could address.

## 4. LITERATURE

Coverage is adequate for a working paper. Key additions made in this round.

## 5. WRITING QUALITY

The prose was substantially improved in this round: opening hook is vivid, results section narrates findings rather than tables, data section uses active voice. The conclusion is the strongest section — memorable and well-crafted.

## 6. CONSTRUCTIVE SUGGESTIONS

1. Future versions should consider PPML estimation as alternative to log(y+0.1).
2. Synthetic control for DC would strengthen the outlier analysis.
3. When FTS distribution data becomes available, dose-response specifications would be valuable.

## 7. OVERALL ASSESSMENT

This paper makes a genuine contribution: it is the first heterogeneity-robust causal analysis of FTS legalization, and it honestly reports a null result that challenges both advocates and critics. The methodology is state-of-the-art for DiD. The main limitation — DC as sole driver of the positive aggregate — is transparently documented and strengthens rather than weakens the paper's credibility. The leave-one-out analysis, state trends, and 1000-permutation RI are all responsive to reviewer concerns.

DECISION: MINOR REVISION
